Clinical trials: Neoplasm, Bronchial
Metastatic NSCLC - Non-Small Cell Lung Cancer, Advanced Solid Tumor
XTX501 in Patients With Metastatic Non-Small Cell Lung Cancer and Advanced Solid Tumors
This is a first-in-human, multicenter, Phase 1/2, open-label study designed to evaluate the safety and tolerability of XTX501 as monotherapy in participants with metastatic non-small cell lung cancer (NSCLC) and select advanced…
- Trial name
- NCT07688577
- Testing
- XTX501
- Volunteers
- 140 people
- Sponsor
- Xilio Development, Inc.
Non Small Cell Lung Cancer
SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.
This multi-center, open label phase II clinical study is performed in patients with locally advanced or metastatic EGFR wild-type ALK wild-type non-small cell lung cancer progressed on prior anti-PD-1 mab ± platinum-based…
- Trial name
- NCT05020457
- Testing
- SI-B001, AP or TP, Docetaxel
- Where
- 6 sites in China
- Volunteers
- 69 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Stage III Non-small Cell Lung Cancer, Unresectable
Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC
The purpose of this study is to compare the clinical activity of durvalumab alone vs durvalumab in combination with novel agents.
- Trial name
- COAST (NCT03822351)
- Testing
- Durvalumab + Oleclumab, Durvalumab, Durvalumab + Monalizumab
- Where
- 73 sites in United States, Canada and 7 more
- Volunteers
- 189 people
- Sponsor
- MedImmune LLC
Non-small Cell Lung Cancer
Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer
This is a multicenter Phase I/II study for patients with advanced non-small cell lung cancer who have failed PD-1/L1 therapy, aiming to evaluate the safety of ZG005 in combination with Gecacitinib in this population, as well as…
- Trial name
- NCT06903377
- Testing
- ZG005 for Injection, Gecacitinib Hydrochloride Tablets
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Non Small Cell Lung Cancer Metastatic
A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With the Therapeutic Vaccine Named TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC)
This is a multicenter, single arm, open label phase II study in treatment-naïve for advanced stage of the disease and immunotherapy-naïve patients with advanced non-squamous NSCLC and with < 50% of tumor cells expressing…
- Trial name
- NCT03353675
- Testing
- TG4010, Chemotherapy, Nivolumab
- Where
- 9 sites in United States, Belgium and 2 more
- Volunteers
- 44 people
- Sponsor
- Transgene
Small Cell Lung Cancer
A Study of PLM60 in Subjects With Relapsed Small-cell Lung Cancer After Platinum-based First-Line Chemotherapy
This is an open, multicenter phase II clinical study for PLM60. The primary aim of the study is to observe the initial efficacy of PLM60 in treatment of small cell lung cancer.
- Trial name
- NCT04352413
- Testing
- PLM60
- Where
- China
- Volunteers
- 45 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of pralsetinib (BLU-667)…
- Conditions
- RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer, RET-altered Colon Cancer
- Trial name
- ARROW (NCT03037385)
- Testing
- pralsetinib (BLU-667)
- Where
- 71 sites in United States, Belgium and 11 more
- Volunteers
- 590 people
- Sponsor
- Hoffmann-La Roche
Hematologic Malignancies, Solid Tumor
A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
Multicenter, open-label, phase 1a/1b trial of PF-07901800 (TTI-621) in subjects with relapsed or refractory hematologic malignancies and selected solid tumors.
- Trial name
- NCT02663518
- Testing
- PF-0791800 (TTI-621), PF-07901800 (TTI-621) plus Rituximab, PF-07901800 (TTI-621) plus Nivolumab
- Where
- 51 sites in United States, Canada
- Volunteers
- 249 people
- Sponsor
- Pfizer
Non Small Cell Lung Cancer
A Study Comparing Two Different Chemotherapy Types in Chinese Patients With Advanced Non Small Cell Lung Cancer
The purpose of this study is to compare the efficacy and safety of two different chemotherapy types in the first line treatment of advanced Non-Small Cell Lung Cancer (NSCLC).
- Trial name
- NCT01005680
- Testing
- Pemetrexed, Gemcitabine, Cisplatin
- Where
- 8 sites in China
- Volunteers
- 256 people
- Sponsor
- Eli Lilly and Company
Non Small Cell Lung Carcinoma, Metastatic Breast Cancer
Non-Interventional Study With Vinorelbine ORAL in Advanced Non-Small Cell Lung Carcinoma(NSCLC) and Metastatic Breast Cancer (MBC)
The purpose of this non-interventional study is to collect data on efficacy and toxicity of the use of Navelbine ORAL in daily routine in Germany (especially after availability of an 80mg capsule).
- Trial name
- NCT00890903
- Where
- Germany
- Volunteers
- 62 people
- Sponsor
- Pierre Fabre Pharma GmbH
Non Small Cell Lung Cancer (NSCLC)
Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer (NSCLC)
The purpose of this study is to estimate and compare the objective response rate of SPI-1620 administered in combination with docetaxel in patients with NSCLC and to determine the safety of SPI-1620 when administered in…
- Trial name
- NCT01741155
- Testing
- SPI-1620, Docetaxel
- Where
- 5 sites in United States
- Volunteers
- 34 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
RET-fusion Non Small Cell Lung Cancer, Lung Neoplasm
External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC
This is an external control, observational, retrospective study designed to compare clinical outcomes for pralsetinib compared with best available therapy for patients with RET-fusion positive advanced NSCLC.
- Conditions
- RET-fusion Non Small Cell Lung Cancer, Lung Neoplasm, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms
- Trial name
- NCT04697446
- Where
- 3 sites in United States, France and 1 more
- Volunteers
- 279 people
- Sponsor
- Blueprint Medicines Corporation
Non-Small-Cell Lung Cancer
Registry for the EVolution Of LUng Cancer Therapy Implementation and Outcomes Now
REVOLUTION will be a US multicenter observational registry in scope and governed by a steering committee of approximately 8 experts in NSCLC and outcomes research.
- Trial name
- REVOLUTION (NCT02835599)
- Where
- 15 sites in United States
- Volunteers
- 23 people
- Sponsor
- AstraZeneca
Extensive-Stage Small-Cell Lung Cancer
Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Patients With Previously Untreated Extensive Stage Small-cell Lung Cancer
The purpose of this study is to determine the maximum tolerated dose and assess the safety, tolerability and activity of carfilzomib given in combination with carboplatin and etoposide as initial therapy for patients with…
- Trial name
- NCT01987232
- Testing
- Carfilzomib, Carboplatin, Etoposide
- Where
- 17 sites in United States, Canada and 1 more
- Volunteers
- 32 people
- Sponsor
- Amgen
Non-small Cell Lung Cancer
A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer
To assess the efficacy and safety of Almonertinib versus placebo following chemoradiation in patients with stage III unresectable epidermal growth factor receptor mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC).
- Trial name
- NCT04951635
- Testing
- Almonertinib
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Small-Cell Lung Cancer
Study of AZD2811 + Durvalumab in ES-SCLC
A Phase II Multicenter, Open-Label, Single Arm Study to Determine the Efficacy, Safety and Tolerability of AZD2811 and Durvalumab Combination as Maintenance Therapy After Induction with Platinum-Based Chemotherapy Combined with…
- Trial name
- TAZMAN (NCT04745689)
- Testing
- Durvalumab, AZD2811, Carboplatin
- Where
- 12 sites in United States, Poland and 2 more
- Volunteers
- 31 people
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer
The purpose of this two-stage phase II study is to assess the efficacy of BKM120, as measured by determining the progression free survival (PFS), in patients with pretreated metastatic Non-small Cell Lung Cancer (NSCLC) that…
- Trial name
- BASALT-1 (NCT01297491)
- Testing
- BKM120
- Where
- 92 sites in United States, Argentina and 16 more
- Volunteers
- 63 people
- Sponsor
- Novartis Pharmaceuticals
Small Cell Lung Cancer
Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer
The study seeks to assess the efficacy of veliparib (ABT-888) in combination with carboplatin and etoposide in participants with extensive disease small cell lung cancer (ED SCLC).
- Trial name
- NCT02289690
- Testing
- Veliparib, Carboplatin, Etoposide
- Where
- 62 sites in United States, Australia and 10 more
- Volunteers
- 221 people
- Sponsor
- AbbVie
Non Small Cell Lung Cancer
Jinfukang Oral Liquid Combined With Chemotherapy for Treating Driver Gene-negative Advanced NSCLC
This is a prospective, randomized, multicenter real-world study, which aims to investigate the efficacy and safety of Jinfukang oral liquid combined with chemotherapy as first-line treatment regimen for patients with…
- Trial name
- NCT05098990
- Testing
- Jinfukang oral liquid, Platinum-based doublet chemotherapy
- Volunteers
- 328 people
- Sponsor
- China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
Carcinoma, Non-Small-Cell Lung
A Study in Participants With First-Line Nivolumab Plus Ipilimumb Therapy Combined With Two Cycles of Chemotherapy for Metastatic Non-Small Cell Lung Cancer
The purpose of the study is to collect real-life data during the early post-market authorization approval period in Germany. The study aims at describing the outcomes, patient characteristics, safety profile, treatment patterns…
- Trial name
- FINN (NCT04794010)
- Where
- Germany
- Volunteers
- 825 people
- Sponsor
- Bristol-Myers Squibb
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.